"Setback for Amylyx: Relyvrio ALS Drug Trial Results in Regulatory Uncertainty"
TL;DR Summary
Amylyx Pharmaceuticals' ALS drug, Relyvrio, failed to show any benefit for patients in a large clinical trial, prompting the company to consider a voluntary withdrawal of the approved medicine from the market. The Phase 3 study involving 664 people with ALS revealed that Relyvrio did not outperform a placebo on an ALS functional rating scale, indicating no benefit at all.
- In stunning outcome, Amylyx's ALS drug fails large clinical trial STAT
- A.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Market The New York Times
- Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS Yahoo Finance
- Amylyx Pharmaceuticals Shares Plummet After Relyvrio Trial Misses Endpoints MarketWatch
- New ALS Treatments Face Regulatory Uncertainty BioSpace
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
74%
235 → 60 words
Want the full story? Read the original article
Read on STAT